Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Bennett

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.
Blood Advances|October 19, 2022
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDSMaximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Nature Medicine|August 5, 2020
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.
Blood Advances|October 19, 2022
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDSMaximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Nature Medicine|August 5, 2020
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 17